{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-058821","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2024-07-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.978262+00:00","generated_at":"2026-05-31T23:39:02.206454+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Emmaus 2023 revenue up 61% to $29.6M, net loss narrows to $3.7M","bullets":["Net revenue $29.6M (vs $18.4M in 2022); operating income $3.5M vs loss $6.6M.","Net loss $3.7M ($0.07/sh) vs $10.6M ($0.21/sh); cash $2.5M at Dec 31, 2023.","MENA region and U.S. sales drove growth; disposed of Japanese JV equity interest.","Inventory shortage impacted Q4 2023 sales; backlog ~$4.6M as of May 24, 2024; now resolved."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-058821","json":"https://secwatch.observer/filing/0001213900-24-058821.json","markdown":"https://secwatch.observer/filing/0001213900-24-058821.md","text":"https://secwatch.observer/filing/0001213900-24-058821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390024058821/0001213900-24-058821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390024058821/ea0207151-8k_emmaus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:39:02.206454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}